WCN'24 APOL1 Targeted Therapies: Who to Test and Which Disease to Treat?


Back to Package

Genetic variants in APOL1 are a major contributor to the increased risk of kidney disease in people of recent African ancestry. In this session, recent insight into the contribution of the APOL1 risk genotype to different renal phenotypes will be highlighted, as well as the difficulty in determining when to when to screen and where to apply APOL1 genotype data in clinical practice. In addition, a long-lasting study showing the promise of a small-molecule inhibitor of APOL1 channel function as potential treatment will be discussed.

Ana Iltis

USA

Saraladevi Naicker

South Africa

Dwomoa Adu

Ghana

Ogo Egbuna

USA

Key:

Complete
Failed
Available
Locked
Ethical Aspects of Race-based Genetic Testing
Open to view video.
Open to view video.
You must register to access.
Contribution of ApoL1 Risk Genotype to HIVAN
Open to view video.
Open to view video.
You must register to access.
Contribution of APOL1 Risk Alleles to Kidney Disease in West Africa
Open to view video.
Open to view video.
You must register to access.
Targeting ApoL1: A 12-Year Journey from Genetic Discovery to Phase 2 Trials
Open to view video.
Open to view video.
You must register to access.
Q and A
Open to view video.
Open to view video.
You must register to access.